We and others have shown that Mcl-1 was essential for the survival of human myeloma cells in vitro. Furthermore, this antiapoptotic protein is upregulated by interleukin-6, which plays a critical role in multiple myeloma (MM). For these reasons, we have evaluated the expression of Mcl-1 in vivo in normal, reactive and malignant plasma cells (PC), that is, myeloma cells from 51 patients with MM and 21 human myeloma cell lines (HMCL) using flow cytometry. We show that Mcl-1 is overexpressed in MM in comparison with normal bone marrow PC. In total, 52% of patients with MM at diagnosis (P ¼ 0.017) and 81% at relapse (P ¼ 0.014 for comparison with diagnosis) overexpress Mcl-1. Of note, only HMCL but not reactive plasmacytoses have abnormal Mcl-1 expression, although both PC expansions share similar high proliferation rates. Of interest, Bcl-2 as opposed to Mcl-1, does not discriminate malignant from normal PC. Finally, the level of Mcl-1 expression is related to disease severity, the highest values at diagnosis being associated with the shortest eventfree survival (P ¼ 0.002). In conclusion, Mcl-1, which has been shown to be essential for the survival of human myeloma cells in vitro, is overexpressed in vivo in MM in relation with relapse and shorter survival. Mcl-1 represents a potential therapeutical target in MM.
Introduction
Multiple myeloma (MM) is a rapidly fatal plasma-cell malignancy that evolves mainly in the bone marrow. Myeloma cells proliferate very slowly and display a weak apoptotic index in vivo. Whether this is due to abnormalities of cell cycle or apoptosis remains pending. In any case, myeloma cells turn out to be resistant to chemotherapy and the prognosis of the disease remains poor. 1 Understanding the mechanisms of survival of myeloma cells within the bone marrow and of escape (resistance) of these cells to chemotherapy is a major challenge in order to define new therapeutical targets and treatments. Many studies have shown that both the survival and resistance to chemotherapy of myeloma cells was dependent on (i) bone marrow environment, (ii) capacity of myeloma cells to interact with this environment and (iii) survival and growth factors supplied by this environment (reviewed in Nefedova et al 2 ). The expression of the prosurvival members of the Bcl-2 family has been shown to be a key process in the survival of myeloma cells. More particularly, Mcl-1 expression turned out to be critical for their survival. 3, 4 Indeed, knockdown of Mcl-1 by antisenses induces apoptosis in myeloma cells whereas Bcl-2 or Bcl-xL antisenses have few or no effect. [4] [5] [6] Moreover, a critical threshold level of Mcl-1 is necessary for viability of myeloma cells. 3 Finally, Mcl-1 was found to be the only antiapoptotic Bcl-2 family member, whose level of expression was modified by cytokine treatment of myeloma cells. [7] [8] [9] [10] These data suggest that increased levels of Mcl-1 during disease progression could be an important mechanism in the acquisition of resistance to chemotherapy in MM. Surprisingly, expression of Mcl-1 has not been evaluated in MM in vivo at diagnosis and during disease progression, data being available only on a small number of patients. 11 Thus, we used flow cytometry to evaluate the expression of Mcl-1 in normal, reactive and malignant plasma cells (PC), that is, myeloma cells from 51 patients with MM, either at diagnosis or relapse and 21 human myeloma cell lines (HMCL).
Materials and methods
Mononuclear bone marrow and peripheral blood PC, freshly explanted human myeloma cells and HMCL Seven bone marrow samples came from healthy bone marrow donors during the process of bone marrow transplantation. In total, 51 consecutive patients with MM were evaluated, including 25 newly diagnosed patients and 26 at the time of medullary relapse. No serial study of individual patients could be performed. All the patients at diagnosis had symptomatic disease and fulfilled the diagnostic criteria of the Southwest Oncology Group of United States of America. 12 Relapse was defined by the occurrence of any new symptom relevant to MM (mainly anemia and/or new lytic bone lesions) and/or increase of the monoclonal component 425% above previous level. The University Hospital of Nantes review board approved these studies. Informed consent was provided according to the Declaration of Helsinki. In total, 21 HMCL were included in this study, commercially available (U266, LP1, L363, OPM2, NCIH929, RPMI8226, JJN3), gifts (JIM3 from Leiff Bergsagel, Cornell University, NY, USA and KMS12PE, KMS18, KMS11, KMS12BM, 13 or established by ourselves (NAN1, NAN2, NAN3, XG1, XG2, XG6, MDN, SBN, BCN).
Eight cases of reactive plasmacytoses (RP) were studied. In all these cases, transient polyclonal circulating PC were observed in the peripheral blood. These RP were detected initially by cytological identification of PC on smears and a final diagnosis was established by immunophenotyping. 14 
Monoclonal antibodies (mAbs) and reagents
Anti-CD45 (clone J33), anti-CD138 (B-B4) were purchased from Beckman Coulter (Miami, F, USA). Anti-CD38 (HB7) and isotype control mAbs were from BD Bioscience (San Jose, CA, USA) and anti-Bcl-2 from Dako (Glostrup, Denmark). The anti-Mcl-1mAb (clone 22), directly conjugated to PE, was customized by BD Bioscience (San Jose, CA, USA).
Cell staining for immunophenotyping
Since Gojo et al 15 have shown that Mcl-1 mRNA and protein both have a short half-life in MM cells, cells were treated within 2 h following bone marrow aspiration. After ficoll density separation, bone marrow mononuclear cells (5 Â 10 5 ) were stained in a four-color assay with optimal concentration of each mAb per test. For staining of surface molecules, mononuclear cells were incubated 20 min at room temperature with 10 ml volumes of pretitrated antibody: anti-CD38-APC, anti-CD45 (FITC or PC5) and anti-CD138 (PC5 or Phyco-erythrin (PE)) mAbs, in PBS containing 20% AB serum. Then, the mononuclear cells were washed twice and permeabilized using Intra prep permeabilization reagent (Beckman Coulter) recommended by the manufacturer and stained with anti-Mcl-1-PE or anti-Bcl-2-FITC and with the control isotype-PE or FITC mAbs. The cells were fixed in PBS 1% formaldehyde.
Flow cytometry analysis
Data were acquired by means of a Becton Dickinson FACS Calibur with CellQuest Pro software (BD Bioscience). To increase the sensitivity and accuracy of the analysis, acquisition was performed in two consecutive steps: in the first step, a total of 15 000 events/tube was acquired and in the second step acquisition through a large 'live-gate' drawn on SSC log/CD38 strongly positive cells was performed. In this latter step, a minimum of 1000 PC was acquired. 16 For analysis, PC were identified using a sequential gating strategy: an initial region (R1) was set around cells expressing a high level of CD38 with their typical side scatter and then a second region (R2) was set on the CD38 vs CD138. To exclude contaminating events as well as apoptotic cells and cellular debris, the third region (R3) was set on the side light scatter (SSC) vs the forward light scatter (FSC).
The final PC gate used was a combination of R1, R2 and R3 (CD38, CD138, scatter characteristics). Analysis of CD38 vs CD138 expression provides the best separation of PC from other leucocytes. The mean fluorescence intensity ratio (MFIR) was obtained by dividing the mean fluorescence intensity of each antigen by the mean fluorescence intensity of its isotypic control.
Survival analysis
In total, 25 patients (median age 65 years) with newly diagnosed MM received treatments according to ongoing protocols of the IFM group, and are included in the survival analysis. Overall survival (OS) was calculated from the first day of treatment to the date of death, and event-free survival (EFS) was calculated from the first day of treatment to the date of relapse, progression or death. Analysis of prognostic factors for survival was performed including usual clinical (age, sex), biological (isotype, b 2 -microglobulin, CRP, creatinine, hemoglobin, albumin, calcium) and cytogenetic (chromosome 13 deletion and 14q32 rearrangement) characteristics at presentation, and the level of Mcl-1 expression.
Statistical analysis
For statistical analysis, we used nonparametric tests, that is, the Wilcoxon rank sum test, the Fisher exact test and the w 2 method when appropriate. Curves for OS and EFS were plotted according to the method of Kaplan and Meier and were compared by the log-rank test. Multivariate analysis was performed using the Cox model.
Results

Mcl-1 is overexpressed in MM patients
The level of expression of Mcl-1 was determined by a four-color immunofluorescence analysis in normal PC and in myeloma cells from MM at diagnosis. All bone marrow PC from healthy donors expressed Mcl-1. The intensity of protein expression is defined by the MFIR. MM patients at diagnosis did also express Mcl-1 on the whole malignant cell population. Myeloma cells at diagnosis have a higher MFIR of Mcl-1 than normal bone marrow PC (median value: 11.7, range 4-22 vs 8.7, range 5-9.7, P ¼ 0.025) (Figure 1a) . Furthermore, 52% of MM at diagnosis presented abnormal Mcl-1 expression (P ¼ 0.025) (ie, Mcl-1 expression above the upper limit defined by 2 standard deviations above the mean value of normal PC). Of note, when Bcl-2 expression was considered, no difference was found between normal bone marrow PC and myeloma cells at diagnosis (7.2, range 3-16 vs 5.7 range 4-10) (Figure 1c ).
Mcl-1 expression correlates with disease progression
To investigate the clinical significance of Mcl-1 in MM, we investigated its expression in MM patients either at diagnosis (n ¼ 25) or relapse (n ¼ 26). Analysis of the MFIR of Mcl-1 indicated a median value of 11.7 (range 4-22) for MM patients at diagnosis vs 15 (range 6-30) for patients at relapse (P ¼ 0.04) (Figure 1a ). In total, 81% of MM patients at relapse had abnormal Mcl-1 expression as opposed to 52% at diagnosis (P ¼ 0.04). These results clearly indicated an increase of Mcl-1 expression at the time of relapse and thus during disease progression. However, serial studies in individual patients will be necessary to confirm this concept. Of note, when Bcl-2 expression was considered, no difference was found between MM at diagnosis and MM in relapse (7.2, range 3-16 vs 9, range 3-20 ( Figure 1c ).
HMCL but not reactive plasmocytoses (RP) overexpress Mcl-1
To see whether or not the overexpression of Mcl-1 in MM was related to malignancy and not simply to excess of proliferation, we compared its expression between HMCL and RP, both situations in which the labeling index was 420%.
14 Only intrinsic malignancy discriminate HMCL from RP. Of note, HMCL overexpress Mcl-1 (P ¼ 0.01) (median value: 13.5, range 7.4-29) whereas 3 RP had low Mcl-1 expression (median value: 5, range 2.5-5) (Figure 1b) . On the other hand, when Bcl-2 was considered, low values were observed in both HMCL and RP (Figure 1d ) as previously described.
14 However, a larger number of RP with Mcl-1 expression evaluation will be necessary.
Mcl-1 expression correlates with disease severity and clinical outcome
In this group of 25 newly diagnosed patients, two deaths were observed due to progressive disease, with a median follow-up for living patients of 12 months (range: 4-40). The OS was 90.7% at 40 months ( þ 6%). The median EFS was 26 months for the whole group of patients (range: 4-40). The single factor influencing EFS was the level of Mcl-1 expression (median MFIR: 13, range: 5.8-22). The median duration of EFS was 12 months (range: 4-18) in the group of 11 patients with an abnormal expression of Mcl-1 (two deaths and three relapses were observed), as compared with an EFS of 66.7% at 40 months (median not reached) in the group of 14 patients with a normal expression of Mcl-1 (1 relapse observed) (P ¼ 0.002) (Figure 2 ). These two groups of patients (normal and abnormal expression of Mcl-1) were identical regarding initial characteristics and regarding treatment regimen: the percentage of patients treated with either conventional treatment, or single autologous stem cells transplantation, or tandem transplant was similar in both groups of patients. In this small cohort of patients, chromosome 13 deletion, beta-2-microglobulin level or other presenting features did not statistically influence survival as single parameters. Mcl-1 expression in normal and malignant human plasma cells S Wuillème-Toumi et al
Discussion
A critical role of Mcl-1 has been established in the biology of MM. 4, 17, 18 However, its expression has never been evaluated in vivo in patients with MM. For these reasons, we have evaluated the expression of Mcl-1 in both normal (bone marrow), reactive (RP) and malignant (MM and HMCL) PC. Of note, RP are characterized by expansion of highly proliferative normal PC progenitors and precursors (labeling index 420%) as previously described by ourselves, 14 whereas HMCL are expansions of highly proliferative malignant PC.
By evaluating the level of Mcl-1 expression in myeloma cells of patients either at diagnosis or relapse in comparison with that of normal PC in the bone marrow, we have shown that about half of MM patients at diagnosis and more than three quarters of MM patients at the time of relapse overexpress Mcl-1. The correlation of Mcl-1 expression with disease activity is confirmed by the high expression of Mcl-1 we found in more than 80% of HMCL. In comparison, Bcl-2 did not discriminate MM from normal PC. Thus, although it is not (yet) possible to evaluate any correlation between Mcl-1 expression and sensitivity to chemotherapy (achievement of complete remission), we have already shown that overexpression of Mcl-1 directly correlates with disease status generally associated with chemoresistance (relapses, terminal phase with immortalization). Finally, this is confirmed by the significant impact of Mcl-1 on EFS. However, further investigation will be necessary to confirm these points, that is, (i) real upregulation of Mcl-1 during disease progression in individual patients, and (ii) the final impact of Mcl-1 on the clinical outcome of patients with MM.
Although the number of RP is too low to draw any conclusion, the low levels of Mcl-1 detected in these three cases are of major importance. RP have been already characterized by their high labeling index and low expression of Bcl-2. With regard to Mcl-1, their comparison with highly proliferative myeloma cells (HMCL) is of major interest. Indeed, in these cases of HMCL (ie, with a labeling index ranging from 25 to 30% as that of RP), Bcl-2 is low but Mcl-1 is high. Thus, Mcl-1 but not Bcl-2 discriminates RP from HMCL, that is, normal from malignant expansions of PC. This shows that the overexpression of Mcl-1 is clearly related to malignancy rather than to simply proliferation.
The molecular mechanisms involved in this malignant overexpression turn out to be a major challenge for the next future to clarify the pathogenesis of MM. It will be more particularly important to know whether the overexpression of Mcl-1 is related to an abnormal response to cytokines like interleukin-6 or to mutations of the promoter of the Mcl-1 gene, a mechanism recently involved in chronic lymphocytic leukemia. Mcl-1 expression in normal and malignant human plasma cells S Wuillème-Toumi et al
